HK1256814A1 - 用於在药物中使用的胶体颗粒 - Google Patents
用於在药物中使用的胶体颗粒 Download PDFInfo
- Publication number
- HK1256814A1 HK1256814A1 HK18115899.0A HK18115899A HK1256814A1 HK 1256814 A1 HK1256814 A1 HK 1256814A1 HK 18115899 A HK18115899 A HK 18115899A HK 1256814 A1 HK1256814 A1 HK 1256814A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- medicine
- colloidal particles
- composition
- contain
- active agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dispersion Chemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1518172.0A GB201518172D0 (en) | 2015-10-14 | 2015-10-14 | Colloidal particles for use in medicine |
| GB20150018172 | 2015-10-14 | ||
| PCT/EP2016/074759 WO2017064276A1 (en) | 2015-10-14 | 2016-10-14 | Colloidal particles for use in medicine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1256814A1 true HK1256814A1 (zh) | 2019-10-04 |
Family
ID=55131025
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK18115899.0A HK1256814A1 (zh) | 2015-10-14 | 2016-10-14 | 用於在药物中使用的胶体颗粒 |
Country Status (15)
| Country | Link |
|---|---|
| US (3) | US20190192664A1 (https=) |
| EP (1) | EP3362039A1 (https=) |
| JP (1) | JP7160678B2 (https=) |
| KR (1) | KR20180067616A (https=) |
| CN (1) | CN108472246A (https=) |
| AU (1) | AU2016336929B2 (https=) |
| BR (1) | BR112018007399A2 (https=) |
| CA (1) | CA3036111C (https=) |
| EA (1) | EA201890703A1 (https=) |
| GB (1) | GB201518172D0 (https=) |
| HK (1) | HK1256814A1 (https=) |
| IL (1) | IL258567B2 (https=) |
| MX (1) | MX391574B (https=) |
| SG (2) | SG11201802956RA (https=) |
| WO (1) | WO2017064276A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4055032A1 (en) * | 2019-11-07 | 2022-09-14 | The Board Of Trustees Of The University Of Illinois | Peptides and methods of treating sepsis, atherosclerosis, thrombosis, stroke, heart attack and inflammation |
| GB202111759D0 (en) * | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles |
| GB202111758D0 (en) * | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
| GB202111757D0 (en) * | 2021-08-17 | 2021-09-29 | Cantab Biopharmaceuticals Patents Ltd | Modified colloidal particles for use in the treatment of haemophilia A |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| JPH09501169A (ja) | 1993-08-06 | 1997-02-04 | オパーバス ホールディング ビー ヴィ | 小胞に生体高分子物質を高度に充填する方法 |
| JP4545928B2 (ja) | 1998-04-27 | 2010-09-15 | ジリップ・ファーマ・ビー．ブイ． | 第ｖｉｉｉ因子及び中性リポソームを含有する薬学的組成物 |
| US6294192B1 (en) * | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| KR100758158B1 (ko) | 1999-07-14 | 2007-09-12 | 알자 코포레이션 | 중성 지질중합체 및 그를 함유하는 리포솜 조성물 |
| US20030232075A1 (en) * | 2002-05-06 | 2003-12-18 | University Of Minnesota, A Minnesota Corporation | Compositions for producing factor Xa |
| EP1633440B1 (en) * | 2003-04-15 | 2008-05-14 | Opperbas Holding B.V. | Pharmaceutical composition comprising proteins and/or polypeptides and colloidal particles |
| CN101304757A (zh) * | 2005-06-29 | 2008-11-12 | 纽约州立大学研究基金会 | 免疫原性较低的蛋白质-脂质复合物的组合物和方法 |
| MX349417B (es) | 2009-06-03 | 2017-07-28 | Charles Mayo John | Formulaciones para el tratamiento de dolor de tejido profundo. |
| BR112012003834A2 (pt) | 2009-08-21 | 2017-08-08 | Targeted Delivery Tech Limited | métodos para tratamento de distúrbios e para tratamentos de deficiências em ácidos graxos, hipertrigliceridemia ou hipercolesterolemia e pacote |
| GB201007357D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIII |
| GB201007356D0 (en) | 2010-04-30 | 2010-06-16 | Leverton Licence Holdings Ltd | Conjugated factor VIIa |
| MY190257A (en) | 2012-04-16 | 2022-04-11 | Cantab Biopharmaceuticals Patents Ltd | Optimised subcutaneous therapeutic agents |
| EP3608308B1 (en) * | 2013-03-08 | 2021-07-21 | Novartis AG | Lipids and lipid compositions for the delivery of active agents |
-
2015
- 2015-10-14 GB GBGB1518172.0A patent/GB201518172D0/en not_active Ceased
-
2016
- 2016-10-14 EA EA201890703A patent/EA201890703A1/ru unknown
- 2016-10-14 KR KR1020187013254A patent/KR20180067616A/ko not_active Ceased
- 2016-10-14 MX MX2018004445A patent/MX391574B/es unknown
- 2016-10-14 BR BR112018007399A patent/BR112018007399A2/pt not_active Application Discontinuation
- 2016-10-14 EP EP16781807.9A patent/EP3362039A1/en active Pending
- 2016-10-14 SG SG11201802956RA patent/SG11201802956RA/en unknown
- 2016-10-14 HK HK18115899.0A patent/HK1256814A1/zh unknown
- 2016-10-14 AU AU2016336929A patent/AU2016336929B2/en not_active Ceased
- 2016-10-14 JP JP2018519423A patent/JP7160678B2/ja active Active
- 2016-10-14 US US15/768,381 patent/US20190192664A1/en not_active Abandoned
- 2016-10-14 IL IL258567A patent/IL258567B2/en unknown
- 2016-10-14 WO PCT/EP2016/074759 patent/WO2017064276A1/en not_active Ceased
- 2016-10-14 CN CN201680073237.XA patent/CN108472246A/zh active Pending
- 2016-10-14 SG SG10202010711UA patent/SG10202010711UA/en unknown
- 2016-10-14 CA CA3036111A patent/CA3036111C/en active Active
-
2020
- 2020-05-26 US US16/883,338 patent/US20210093721A1/en not_active Abandoned
-
2024
- 2024-06-24 US US18/752,365 patent/US20250170244A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3036111A1 (en) | 2017-04-20 |
| IL258567B2 (en) | 2025-08-01 |
| MX391574B (es) | 2025-03-21 |
| SG10202010711UA (en) | 2020-12-30 |
| JP7160678B2 (ja) | 2022-10-25 |
| US20210093721A1 (en) | 2021-04-01 |
| US20250170244A1 (en) | 2025-05-29 |
| IL258567B1 (en) | 2025-04-01 |
| GB201518172D0 (en) | 2015-11-25 |
| JP2018535952A (ja) | 2018-12-06 |
| BR112018007399A2 (pt) | 2018-10-16 |
| KR20180067616A (ko) | 2018-06-20 |
| EA201890703A1 (ru) | 2018-11-30 |
| EP3362039A1 (en) | 2018-08-22 |
| CA3036111C (en) | 2023-06-06 |
| MX2018004445A (es) | 2018-08-14 |
| CN108472246A (zh) | 2018-08-31 |
| WO2017064276A1 (en) | 2017-04-20 |
| AU2016336929A1 (en) | 2018-05-10 |
| US20190192664A1 (en) | 2019-06-27 |
| SG11201802956RA (en) | 2018-05-30 |
| AU2016336929B2 (en) | 2022-09-29 |
| IL258567A (en) | 2018-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2956871C (en) | Compounds active towards bromodomains | |
| WO2016131067A3 (en) | Pharmaceutical compositions comprising meloxicam | |
| WO2015160975A3 (en) | Combination of a pi3k inhibitor with a bcl-2 inhibitor for use in the treatment of cancer | |
| WO2015165413A8 (zh) | 一种新型的稳定型抗体药物耦联物及其制备方法和用途 | |
| EP3861982A3 (en) | Intracameral implant for treatment of an ocular condition | |
| MX2016014622A (es) | Sistemas de suministro de medicamentos y metodos de uso relacionados. | |
| WO2014180889A8 (en) | Methods and compositions for the treatment of cancer | |
| HK1209343A1 (en) | Etanercept formulations exhibiting marked reduction in sub-visible particles | |
| WO2016040887A3 (en) | Multilamellar lipid vesicle compositions and methods of use | |
| MX2017000041A (es) | Formulaciones de liberacion inmediata disuasivas de abuso que comprenden polisacaridos no celulosicos. | |
| WO2015001087A3 (en) | Drug-delivery composition for topical applications and injections and ophtalmic formulations, method for manufacturing thereof, and methods for delivery a drug-delivery composition | |
| WO2010145849A3 (en) | Drug delivery systems | |
| WO2016140933A3 (en) | Immediate release soluble ibuprofen compositions | |
| HK1256814A1 (zh) | 用於在药物中使用的胶体颗粒 | |
| SMT202200275T1 (it) | Nanoparticelle quali veicoli di rilascio di principi attivi e metodi per la loro produzione | |
| WO2014179615A3 (en) | Biodegradable copolymers, forming and using same | |
| CA3010981A1 (en) | Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers | |
| WO2016001905A3 (en) | Stable liquid ready-to-use injectable formulation of bortezomib | |
| WO2017079403A3 (en) | Polymeric nanoparticles | |
| WO2016036960A8 (en) | Therapeutic nanoparticles and related compositions, methods and systems | |
| IL270159B (en) | Preparations containing nanometer particles for the administration of drugs for the treatment of eye diseases | |
| WO2014165513A3 (en) | Ethylsulfonated hyaluronic acid biopolymers and methods of use thereof | |
| WO2015054208A8 (en) | Injectable compositions | |
| WO2014117010A3 (en) | Composition for ophthalmic administration | |
| WO2012123924A3 (en) | Antimicrobial composition including at least one or more aggregation(s) silver particles |